Gene expression profiling in myelodysplastic syndrome after SPARC overexpression associated with Ara-C

Nian,Qing; Zhang,Zhiqiang; Wei,Chunmei; Kuang,Xingyi; Wang,Xingyong; Wang,Li

doi:10.3892/or.2015.4139

Gene expression profiling in myelodysplastic syndrome after SPARC overexpression associated with Ara-C

Authors:
- Qing Nian
- Zhiqiang Zhang
- Chunmei Wei
- Xingyi Kuang
- Xingyong Wang
- Li Wang
View Affiliations

Affiliations: Department of Emergency, Children's Hospital of Chongqing Medical University, Yuzhong, Chongqing 400016, P.R. China, Department of Hematology, The First Affiliated Hospital of Chongqing Medical University, Yuzhong, Chongqing 400016, P.R. China
Published online on: July 20, 2015 https://doi.org/10.3892/or.2015.4139
Pages: 2072-2082

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Secreted protein acidic and rich in cysteine (SPARC) is involved in many biological processes, including erythropoiesis and cell proliferation. However, the role of SPARC in myelodysplastic syndrome (MDS) remains to be elucidated. Pyrimidine analogue cytosine arabinoside (Ara-C) is among the most effective agents used in the treatment of acute leukemia. The aim of the present study was to determine whether the chemotherapeutic activity of Ara-C was enhanced by the overexpression of SPARC. DNA microarray technology and RNA sequencing were employed to examine differential gene expression in the apoptosis signaling pathway after gene change occurred in cells following drug treatment. The results showed that upregulation of the expression of SPARC induced SKM-1 cell death and inhibited proliferation. Additionally, the apoptotic rate of SPARC overexpression combined with Ara-C increased significantly. Transcription factors CPBP and ZNF333 regulated the 69 genes and long non-coding RNA (lncRNA). Moreover, the mRNA and protein expression of apoptosis-related genes in the DNA microarray results were increased. These results suggest that SPARC expression changes with Ara-C, revealing a possible application in the treatment of MDS.

View Figures

View References

1	Ghariani I, Braham N, Hassine M and Kortas M: Myelodysplastic syndrome classification. Ann Biol Clin. 71:139–144. 2013.In French.
2	Jädersten M and Hellström-Lindberg E: New clues to the molecular pathogenesis of myelodysplastic syndromes. Exp Cell Res. 316:1390–1396. 2010. View Article : Google Scholar : PubMed/NCBI
3	Visconte V, Selleri C, Maciejewski JP and Tiu RV: Molecular pathogenesis of myelodysplastic syndromes. Transl Med UniSa. 8:19–30. 2014.PubMed/NCBI
4	DiMartino JF, Lacayo NJ, Varadi M, Li L, Saraiya C, Ravindranath Y, Yu R, Sikic BI, Raimondi SC and Dahl GV: Low or absent SPARC expression in acute myeloid leukemia with MLL rearrangements is associated with sensitivity to growth inhibition by exogenous SPARC protein. Leukemia. 20:426–432. 2006. View Article : Google Scholar : PubMed/NCBI
5	Rotllant J, Liu D, Yan YL, Postlethwait JH, Westerfield M and Du SJ: Sparc (Osteonectin) functions in morphogenesis of the pharyngeal skeleton and inner ear. Matrix Biol. 27:561–572. 2008. View Article : Google Scholar : PubMed/NCBI
6	Hsiao YH, Lien HC, Hwa HL, Kuo WH, Chang KJ and Hsieh FJ: SPARC (osteonectin) in breast tumors of different histologic types and its role in the outcome of invasive ductal carcinoma. Breast J. 16:305–308. 2010. View Article : Google Scholar : PubMed/NCBI
7	Wiese AH, Auer J, Lassmann S, Nährig J, Rosenberg R, Höfler H, Rüger R and Werner M: Identification of gene signatures for invasive colorectal tumor cells. Cancer Detect Prev. 31:282–295. 2007. View Article : Google Scholar : PubMed/NCBI
8	Said N, Frierson HF Jr, Chernauskas D, Conaway M, Motamed K and Theodorescu D: The role of SPARC in the TRAMP model of prostate carcinogenesis and progression. Oncogene. 28:3487–3498. 2009. View Article : Google Scholar : PubMed/NCBI
9	Isler SG, Ludwig CU, Chiquet-Ehrismann R and Schenk S: Evidence for transcriptional repression of SPARC-like 1, a gene downregulated in human lung tumors. Int J Oncol. 25:1073–1079. 2004.PubMed/NCBI
10	Boultwood J, Pellagatti A, Cattan H, Lawrie CH, Giagounidis A, Malcovati L, Della Porta MG, Jädersten M, Killick S, Fidler C, et al: Gene expression profiling of CD34⁺ cells in patients with the 5q-syndrome. Br J Haematol. 139:578–589. 2007. View Article : Google Scholar : PubMed/NCBI
11	Duong VH, Komrokji RS and List AF: Efficacy and safety of lenalidomide in patients with myelodysplastic syndrome with chromosome 5q deletion. Ther Adv Hematol. 3:105–116. 2012. View Article : Google Scholar
12	Koren-Michowitz M, Maayan H, Apel A, Shem-Tov N, Yerushalmi R, Volchek Y, Avigdor A, Shimoni A and Nagler A: Salvage therapy with ARA-C and gemtuzumab ozogamicin in AML patients relapsing after stem cell transplantation. Ann Hematol. 94:375–378. 2015. View Article : Google Scholar
13	Strauss C, Endimiani A and Perreten V: A novel universal DNA labeling and amplification system for rapid microarray-based detection of 117 antibiotic resistance genes in Gram-positive bacteria. J Microbiol Methods. 108:25–30. 2015. View Article : Google Scholar
14	Prieto C, Risueño A, Fontanillo C and De las Rivas J: Human gene coexpression landscape: Confident network derived from tissue transcriptomic profiles. PLoS One. 3:e39112008. View Article : Google Scholar : PubMed/NCBI
15	Jing Z, Liu Y, Dong M, Hu S and Huang S: Identification of the DNA binding element of the human ZNF333 protein. J Biochem Mol Biol. 37:663–670. 2004. View Article : Google Scholar : PubMed/NCBI
16	Slavin D, Sapin V, López-Diaz F, Jacquemin P, Koritschoner N, Dastugue B, Davidson I, Chatton B and Bocco JL: The Krüppel-like core promoter binding protein gene is primarily expressed in placenta during mouse development. Biol Reprod. 61:1586–1591. 1999. View Article : Google Scholar : PubMed/NCBI
17	Alachkar H, Santhanam R, Maharry K, Metzeler KH, Huang X, Kohlschmidt J, Mendler JH, Benito JM, Hickey C, Neviani P, et al: SPARC promotes leukemic cell growth and predicts acute myeloid leukemia outcome. J Clin Invest. 124:1512–1524. 2014. View Article : Google Scholar : PubMed/NCBI
18	Pellagatti A, Jädersten M, Forsblom AM, Cattan H, Christensson B, Emanuelsson EK, Merup M, Nilsson L, Samuelsson J, Sander B, et al: Lenalidomide inhibits the malignant clone and up-regulates the SPARC gene mapping to the commonly deleted region in 5q-syndrome patients. Proc Natl Acad Sci USA. 104:11406–11411. 2007. View Article : Google Scholar
19	Kimura S, Kuramoto K, Homan J, Naruoka H, Ego T, Nogawa M, Sugahara S and Naito H: Antiproliferative and antitumor effects of azacitidine against the human myelodysplastic syndrome cell line SKM-1. Anticancer Res. 32:795–798. 2012.PubMed/NCBI
20	Nakagawa T and Matozaki S: The SKM-1 leukemic cell line established from a patient with progression to myelomonocytic leukemia in myelodysplastic syndrome (MDS)-contribution to better understanding of MDS. Leuk Lymphoma. 17:335–339. 1995. View Article : Google Scholar : PubMed/NCBI
21	Nian Q, Xiao Q, Wang L, Luo J, Chen LP, Yang ZS and Liu L: SPARC silencing inhibits the growth of acute myeloid leukemia transformed from myelodysplastic syndrome via induction of cell cycle arrest and apoptosis. Int J Mol Med. 33:856–862. 2014.PubMed/NCBI
22	Lu J, Li M, Zhang R, Hu C, Wang C, Jiang F, Yu W, Qin W, Tang S and Jia W: A common genetic variant of FCN3/CD164L2 is associated with essential hypertension in a Chinese population. Clin Exp Hypertens. 34:377–382. 2012. View Article : Google Scholar : PubMed/NCBI
23	Dondelinger Y, Declercq W, Montessuit S, Roelandt R, Goncalves A, Bruggeman I, Hulpiau P, Weber K, Sehon CA, Marquis RW, et al: MLKL compromises plasma membrane integrity by binding to phosphatidylinositol phosphates. Cell Rep. 7:971–981. 2014. View Article : Google Scholar : PubMed/NCBI
24	Mansouri S, Barde S, Ortsäter H, Eweida M, Darsalia V, Langel U, Sjöholm A, Hökfelt T and Patrone C: GalR3 activation promotes adult neural stem cell survival in response to a diabetic milieu. J Neurochem. 127:209–220. 2013. View Article : Google Scholar : PubMed/NCBI
25	Close P, Gillard M, Ladang A, Jiang Z, Papuga J, Hawkes N, Nguyen L, Chapelle JP, Bouillenne F, Svejstrup J, et al: DERP6 (ELP5) and C3ORF75 (ELP6) regulate tumorigenicity and migration of melanoma cells as subunits of Elongator. J Biol Chem. 287:32535–32545. 2012. View Article : Google Scholar : PubMed/NCBI
26	Meyer JA, Wang J, Hogan LE, Yang JJ, Dandekar S, Patel JP, Tang Z, Zumbo P, Li S, Zavadil J, et al: Relapse-specific mutations in NT5C2 in childhood acute lymphoblastic leukemia. Nat Genet. 45:290–294. 2013. View Article : Google Scholar : PubMed/NCBI
27	Hubalek M, Buchner H, Mörtl MG, Schlembach D, Huppertz B, Firulovic B, Köhler W, Hafner E, Dieplinger B, Wildt L, et al: The vitamin E-binding protein afamin increases in maternal serum during pregnancy. Clin Chim Acta. 434:41–47. 2014. View Article : Google Scholar : PubMed/NCBI
28	Johnson EJ: Age-related macular degeneration and antioxidant vitamins: Recent findings. Curr Opin Clin Nutr Metab Care. 13:28–33. 2010. View Article : Google Scholar
29	Gill G: Regulation of the initiation of eukaryotic transcription. Essays Biochem. 37:33–43. 2001. View Article : Google Scholar
30	Quek XC, Thomson DW, Maag JL, Bartonicek N, Signal B, Clark MB, Gloss BS and Dinger ME: lncRNAdb v2.0: Expanding the reference database for functional long noncoding RNAs. Nucleic Acids Res. 43(Database issue): D168–D173. 2015. View Article : Google Scholar :
31	Zou Y, Wang Q, Li B, Xie B and Wang W: Temozolomide induces autophagy via ATM-AMPK-ULK1 pathways in glioma. Mol Med Rep. 10:411–416. 2014.PubMed/NCBI
32	Cowley AW Jr, Moreno C, Jacob HJ, Peterson CB, Stingo FC, Ahn KW, Liu P, Vannucci M, Laud PW, Reddy P, et al: Characterization of biological pathways associated with a 1.37 Mbp genomic region protective of hypertension in Dahl S rats. Physiol Genomics. 46:398–410. 2014. View Article : Google Scholar : PubMed/NCBI
33	Cubillos-Rojas M, Amair-Pinedo F, Peiró-Jordán R, Bartrons R, Ventura F and Rosa JL: The E3 ubiquitin protein ligase HERC2 modulates the activity of tumor protein p53 by regulating its oligomerization. J Biol Chem. 289:14782–14795. 2014. View Article : Google Scholar : PubMed/NCBI
34	Liebermann DA, Hoffman B and Vesely D: p53 induced growth arrest versus apoptosis and its modulation by survival cytokines. Cell Cycle. 6:166–170. 2007. View Article : Google Scholar : PubMed/NCBI
35	Boultwood J, Pellagatti A and Wainscoat JS: Haploinsufficiency of ribosomal proteins and p53 activation in anemia: Diamond-Blackfan anemia and the 5q-syndrome. Adv Biol Regul. 52:196–203. 2012. View Article : Google Scholar
36	Goldberg L, Tijssen MR, Birger Y, Hannah RL, Kinston SJ, Schütte J, Beck D, Knezevic K, Schiby G, Jacob-Hirsch J, et al: Genome-scale expression and transcription factor binding profiles reveal therapeutic targets in transgenic ERG myeloid leukemia. Blood. 122:2694–2703. 2013. View Article : Google Scholar : PubMed/NCBI
37	Linden F, Domschke G, Erbel C, Akhavanpoor M, Katus HA and Gleissner CA: Inflammatory therapeutic targets in coronary atherosclerosis-from molecular biology to clinical application. Front Physiol. 5:4552014. View Article : Google Scholar : PubMed/NCBI